The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a registered offering by Eli Lilly and Company of $5 billion aggregate principal amount of senior notes, consisting of $750 million of its 4.150% notes due 2027, $1 billion of its 4.200% notes due 2029, $1.25 billion of its 4.600% notes due 2034, $1.25 billion of its 5.050% notes due 2054 and $750 million of its 5.200% notes due 2064.

Eli Lilly and Company is a worldwide research-based pharmaceutical company. The company has been pioneering life-changing discoveries for nearly 150 years, and today its medicines help tens of millions of people across the globe. Eli Lilly manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its products are sold in approximately 105 countries.

The Davis Polk capital markets team included partner Yasin Keshvargar and associates Michael Schuster, Tomisin Ogunsanya and Courtney Wax. The tax team included counsel Yixuan Long and associate Jeff Metzger. The environmental team included counsel Loyti Cheng and associate Timothy J. Sullivan. The intellectual property team included partner David R. Bauer and associate Joshua Shirley. All members of the Davis Polk team are based in the New York office.

Copy link to share post